印度非专利药物出口因安全关切和质量标准而面临挑战,威胁到数百家小公司。 Indian generic drug exports face challenges due to safety concerns and quality standards, threatening hundreds of small firms.

印度仿制药作为全球获取负担得起药品的关键，尽管美国专利到期激增，可能促进出口，但其面临的挑战日益加剧。 Indian generic drugs, vital for global access to affordable medicines, face growing challenges despite a surge in patent expiries in the U.S. that could boost exports. 虽然Cipla和Lupin等公司受益于低成本和美国严格遵守监管规定,但该行业在监督、安全关切有限以及超过60%的小企业面临关闭风险而又不符合最新质量标准的情况下挣扎不休。 While companies like Cipla and Lupin benefit from low costs and strong U.S. regulatory compliance, the industry struggles with limited oversight, safety concerns, and over 60% of small firms at risk of closure without meeting updated quality standards.